Study of Golidocitinib for peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well a drug called Golidocitinib works for people with peripheral T-cell lymphoma (a type of cancer that affects certain white blood cells). If you have started treatment with Golidocitinib in the last 3 months, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of peripheral T-cell lymphoma.
- You must have started a treatment that includes Golidocitinib within the last 3 months.
- You must agree to share your medical records and treatment history for the study.
- You must be willing to follow study instructions and procedures.
- You must sign a consent form showing you understand the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
Hear when a new Peripheral T-cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.